The prognostic value of late gadolinium enhancement in myocarditis and clinically suspected myocarditis: systematic review and meta-analysis

[1] Ferreira VM(2018)Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations J Am Coll Cardiol 72 3158-31762

[2] Schulz-Menger J(1996)Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies Circulation 93 841-842

[3] Holmvang G(2012)2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology Cardiovasc Pathol 21 245-274

[4] Richardson P(2013)Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on myocardial and pericardial diseases Eur Heart J 34 2636-2648

[5] McKenna W(1947)Myocarditis; a classification of 1402 cases Am Heart J 34 827-830

[6] Bristow M(1995)A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators N Engl J Med 333 269-275

[7] Leone O(1867)Incidence, causes, and outcomes of dilated cardiomyopathy in children JAMA 296 1867-1876

[8] Veinot JP(2009)Cardiovascular magnetic resonance in myocarditis: a JACC white paper J Am Coll Cardiol 53 1475-1487

[9] Angelini A(2016)Prognostic value of LGE-CMR in HCM: a meta-analysis JACC Cardiovasc Imaging 9 1392-1402

[10] Caforio AL(2017)Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy: systematic review and meta-analysis JACC Heart Fail 5 28-38

[1] Ferreira VM(2018)Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations J Am Coll Cardiol 72 3158-31762

[2] Schulz-Menger J(1996)Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies Circulation 93 841-842

[3] Holmvang G(2012)2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology Cardiovasc Pathol 21 245-274

[4] Richardson P(2013)Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on myocardial and pericardial diseases Eur Heart J 34 2636-2648

[5] McKenna W(1947)Myocarditis; a classification of 1402 cases Am Heart J 34 827-830

[6] Bristow M(1995)A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators N Engl J Med 333 269-275

[7] Leone O(1867)Incidence, causes, and outcomes of dilated cardiomyopathy in children JAMA 296 1867-1876

[8] Veinot JP(2009)Cardiovascular magnetic resonance in myocarditis: a JACC white paper J Am Coll Cardiol 53 1475-1487

[9] Angelini A(2016)Prognostic value of LGE-CMR in HCM: a meta-analysis JACC Cardiovasc Imaging 9 1392-1402

[10] Caforio AL(2017)Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy: systematic review and meta-analysis JACC Heart Fail 5 28-38